Profile
Dr Sahoo is a scientist at the Institute of Life Sciences, Bhubaneswar, India since 2005. He received his M.Sc. degree in 1994 and Ph. D in 1999 from the University of Delhi, Delhi. He served as a JSPS Postdoctoral fellow at the Department of Microbiology, Kumamoto Universit, Japan from 1999-2001. This was followed by a four-year postdoctoral fellowship at the Nebraska Medical Centre, Omaha, USA from 2001-2005. He has published more than 100 peer reviewed research papers including review articles and book chapters in leading scientific journals. Dr Sahoo has featured as one of the top 2% scientists in the world in the field of Pharmacology and Toxicology (year 2020, 2021 and 2022) in a study by Stanford University, USA. Scientific and Professional Activities, Editorial board member of Current Nanomedicine, Clinical & Experimental Pharmacology, Nanomedicine, Serving Section Editor (cancer section) of Current Pharmaceutical Biotechnology and members of different scientific organizations.
Current Focus Areas
Currently our group is exploring the multimodal effect of phytochemical based nanomedicine (phytonanomedicine) in cancer metabolism, epigenetics, chemoresistance and immunotherapy. We are also investigating the effect of phytonanomedicine to modulate the tumor microenvironment by targeting its various factors like hypoxia, cancer associated fibroblasts and immune cells.
Selected Publications
1. Sa, P., Singh, P., Panda, S., Swain, R. K., Dash, R., and Sahoo, S. K. Reversal of cisplatin resistance in oral squamous cell carcinoma by piperlongumineloaded smart nanoparticles through inhibition of Hippo-YAP signalling pathway. Translational Research, 2024, 268, 63-7.
2. Singh P, Sen K, Sa P, Khuntia A, Raghav SK, Swain RK, Sahoo SK. Piperlongumine based nanomedicine impairs glycolytic metabolism in triple negative breast cancer stem cells through modulation of GAPDH & FBP1. Phytomedicine, 2024, 123, 155181
3. Mohapatra P, Madhulika S, Behera S, Singh P, Sa P, Prasad P, Swain SK and Sahoo SK. Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/b-catenin signalling axis, Molecular Therapy, Nucleic Acid, 2023, 34, 102031.
4. Sa P, Mohapatra P, Swain SS, Khuntia A, and Sahoo SK. Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights, Molecular Pharmaceutics, 2023, 20, 11, 5254–5277
5. Singh P and Sahoo SK. Piperlongumine loaded PLGA nanoparticles inhibit cancer stem-like cells through modulation of STAT3 in atmosphere model of triple negative breast cancer, International Journal of Pharmaceutics, 2022, 616, 121526.